Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
DNA Ginkgo Bioworks Holdings, Inc.
Correspondence to Dr ST Fonseca, Graduate Program in Rehabilitation Science, Physical Therapy Department, Universidade Federal de Minas Gerais, Minas Gerais, Avenida Presidênte Antônio Carlos, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback